Antidepressant drugs promote the heterodimerization of the dopamine D2 and somatostatin Sst5 receptors - Fluorescence in vitro studies

Pharmacological Reports

Volumn 64, Issue 5, 2012, Pages 1253-1258

  Szafran, Kinga ^a   Łukasiewicz, Sylwia ^b   Faron Goŕecka, Agata ^a   Kolasa, Magdalena ^a   Kuśmider, Maciej ^a   Solich, Joanna ^a   Dziedzicka Wasylewska, Marta ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Antidepressants; Dopamine receptor 2; FRET; Heterodimerization; Somatostatin receptor 5

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; SOMATOSTATIN RECEPTOR 5;

ARTICLE; BLEACHING; CELL CULTURE; CONFOCAL MICROSCOPY; DIMERIZATION; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; FLUORESCENCE ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION;

EID: 84873738246     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70921-0     Document Type: Article

References (20)

1. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U: Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2: co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal, 2007, 19, 2304-2316. (Pubitemid 47361686)
2. Baudry A, Mouillet-Richard S, Launay JM, Kellermann O: New views on antidepressant action. Curr Opin Neurobiol, 2011, 21, 1-8.
3. Chesselet MF, Reisine TD: Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei. J Neurosci, 1983, 3, 232-236. (Pubitemid 13193405)
4. Donati RJ, Thukral C, Rasenick MM: Chronic treatment of C6 glioma cells with antidepressant drugs results in a redistribution of Gsα. Mol Pharmacol, 2001, 59, 1426-1432. (Pubitemid 32510107)
5. Dziedzicka-Wasylewska M, Faron-Górecka A, Andrecka J, Polit A, Kuśmider M, Wasylewski Z: Fluorescence studies reveal heterodimerization of dopamine D1 and D2 receptors in the plasma membrane. Biochemistry, 2006, 45, 8751-8759. (Pubitemid 44100672)
6. Engin E, Stellbrink J, Treit D, Dickson CT: Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience, 2008, 157, 666-676.
7. Ferone D: Somatostatin and dopamine receptors. Tumori, 2010, 96, 802-805.
8. Izquierdo-Claros RM, Boyano-Adanez MC, Larsson C, Gustavsson L, Arilla E: Acute effects of D1- and D2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. Mol Brain Res, 1997, 47, 99-107. (Pubitemid 27268265)
9. Łukasiewicz S, Błasiak E, Faron-Górecka A, Polit A, Tworzydło M, Górecki A, Wasylewski Z, Dziedzicka-Wasylewska M: Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane. Pharmacol Rep, 2007, 59, 379-392.
10. Molchan SE, Lawlor BA, Hill JL, Martinez RA, Davis CL, Mellow AM, Rubinow DR, Sunderland T: CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry, 1991, 29, 1110-1118.
11. Nilsson A, Stroth N, Zhang X, Qi H, Falth M, Sköld K, Hoyer D et al.: Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology, 2012, 62, 347-357.
12. Pallis E, Thermos K, Spyraki C: Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. Eur J Neurosci, 2001, 14, 763-767. (Pubitemid 34626003)
13. Pallis E, Vasilaki A, Fehlmann D, Kastellakis A, Hoyer D, Spyraki C, Thermos K: Antidepressants influence somatostatin levels and receptor pharmacology in brain. Neuropsychopharmacology, 2009, 34, 952-963.
14. Patel RC, Lange DC, Patel YC: Photobleaching fluorescence resonance energy transfer reveals ligand-induced oligomer formation of human somatostatin receptor subtypes. Methods, 2002, 27, 340-348.
15. Pei L, Li S, Wang M, Diwan M, Anisman H, Fletcher PJ, Nobrega JN, Liu F: Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med, 2010, 16, 1393-1395.
16. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 2000, 288, 154-157. (Pubitemid 30203051)
17. Rodriguez-Sanchez MN, Puebla L, Lopez-Sanudo S, Rodriguez-Martin E, Martin-Espinosa A, Rodriguez-Pena MS, Juarranz MG, Arilla E: Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus. J Neurosci Res, 1997, 48, 238-248. (Pubitemid 27190904)
18. Rubinow DR: Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry, 1986, 21, 341-365.
19. Thermos K, Radke J, Kastellakis A, Anagnostakis Y, Spyraki C: Dopamine-somatostatin interactions in the rat striatum: an in vivo microdialysis study. Synapse, 1996, 22, 209-216. (Pubitemid 26066439)
20. Tripp A, Kota RS, Lewis DA, Sibille E: Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neurobiol Dis, 2011, 42, 116-124.